These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7897422)

  • 1. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis.
    Brochet B; Guinot P; Orgogozo JM; Confavreux C; Rumbach L; Lavergne V
    J Neurol Neurosurg Psychiatry; 1995 Mar; 58(3):360-2. PubMed ID: 7897422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pilot study of Ginkgolide B, a PAF-acether specific inhibitor in the treatment of acute outbreaks of multiple sclerosis].
    Brochet B; Orgogozo JM; Guinot P; Dartigues JF; Henry P; Loiseau P
    Rev Neurol (Paris); 1992; 148(4):299-301. PubMed ID: 1439458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
    Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP
    Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
    Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
    Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists.
    Vogensen SB; Strømgaard K; Shindou H; Jaracz S; Suehiro M; Ishii S; Shimizu T; Nakanishi K
    J Med Chem; 2003 Feb; 46(4):601-8. PubMed ID: 12570381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAF antagonist ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus.
    Oberpichler H; Sauer D; Rossberg C; Mennel HD; Krieglstein J
    J Cereb Blood Flow Metab; 1990 Jan; 10(1):133-5. PubMed ID: 2298830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BN 52021: a platelet activating factor antagonist for preventing post-transplant renal failure. A double-blind, randomized study. The BN 52021 Study Group in Renal Transplantation.
    Grino JM
    Ann Intern Med; 1994 Sep; 121(5):345-7. PubMed ID: 8042824
    [No Abstract]   [Full Text] [Related]  

  • 9. Ginkgolide BN 52021 protects against hemorrhagic shock-induced renal injury in rats.
    Kirejczyk JK; Chyczewski L; Debek W
    Rocz Akad Med Bialymst; 1995; 40(1):65-76. PubMed ID: 8528996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ginkgolide B on isobaric hypoxic pulmonary hypertension in rats.
    Cheng D; Chen W
    Chin Med J (Engl); 1996 Nov; 109(11):881-4. PubMed ID: 9275375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of ginkgolide B on platelet-activating factor induced activation of rat polymorphonuclear leukocytes].
    Nie ZG; Wang WJ
    Yao Xue Xue Bao; 2003 Feb; 38(2):98-102. PubMed ID: 12778742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitory effect of ginkgolide B on angiogenesis in chronic inflammation].
    Ou-Yang XY; Wang WJ; Liao WH; Chen XH
    Yao Xue Xue Bao; 2005 Apr; 40(4):311-5. PubMed ID: 16011257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
    Hartung HP; Gonsette R; König N; Kwiecinski H; Guseo A; Morrissey SP; Krapf H; Zwingers T;
    Lancet; 2002 Dec 21-28; 360(9350):2018-25. PubMed ID: 12504397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ginkgolide B inhibits platelet release by blocking Syk and p38 MAPK phosphorylation in thrombin-stimulated platelets.
    Liu X; Yan Y; Bao L; Chen B; Zhao Y; Qi R
    Thromb Res; 2014 Nov; 134(5):1066-73. PubMed ID: 25223809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis.
    Wade DT; Young CA; Chaudhuri KR; Davidson DL
    J Neurol Neurosurg Psychiatry; 2002 Sep; 73(3):246-9. PubMed ID: 12185153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gingkolides and bilobalide: structure, pharmacology, and synthesis].
    Sviridov AF
    Bioorg Khim; 1991 Oct; 17(10):1301-12. PubMed ID: 1804115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro effects of ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5 expression in peripheral blood mononuclear cells from asthmatic subjects.
    Mahmoud FF; Abul HT; Haines DD; Abal AT; Wise JA
    Transplant Proc; 2002 Nov; 34(7):2958-61. PubMed ID: 12431672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.